Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.

摘要: Recent studies have demonstrated that tegafur-uracil (UFT) is useful for the adjuvant treatment of various types cancers. To determine whether nucleoside metabolizing enzymes could be used to predict response UFT in women with primary breast cancer, we retrospectively analyzed archived tumor tissue samples obtained from 3rd Adjuvant Chemo-Endocrine Therapy Breast Cancer (ACETBC) study, which tamoxifen (TAM) plus 2 years was compared TAM alone years. Samples were 192 premenopausal node-positive invasive cancer. The examined immunohistochemically study expression thymidylate synthase (TS), thymidine phosphorylase (TP), and dihydropyrimidine dehydrogenase (DPD), as well Her2 p53. In patients TS-positive tumors, risk relapse significantly lower group than group. After years, however, there a trend towards decrease relative predictive value (RPV) TS time. No relationship outcome detected TP or DPD. Expression p53 significant prognostic indicator TS, but not DPD, may predictor therapy. RPV decreased time, suggesting oral fluorouracil derivatives inadequate. Further are required investigate this possibility.